Float Short %

2.11

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

1.8

EPS Last/This Y

3.9

EPS This/Next Y

0.51

Price

1.89

Target Price

Analyst Recom

Performance Q

-13.3

Relative Volume

0.7

Beta

0.27

Ticker: BCLI

20 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2024-12-19	BCLI	2.03	0.02	0.00	787
2024-12-20	BCLI	2.26	0.02	0.00	787
2024-12-23	BCLI	2.05	0.02	0.00	787
2024-12-24	BCLI	2.23	0.02	0.00	787
2024-12-26	BCLI	2.5	N/A	N/A	0
2024-12-27	BCLI	2.44	0.02	0.00	789
2024-12-30	BCLI	2.36	0.02	0.00	849
2024-12-31	BCLI	2.27	0.02	0.00	849
2025-01-02	BCLI	2.14	0.02	0.00	849
2025-01-03	BCLI	2.21	0.02	0.00	849
2025-01-06	BCLI	2.27	0.02	0.00	849
2025-01-07	BCLI	2.22	N/A	N/A	0
2025-01-08	BCLI	2.07	N/A	N/A	0
2025-01-09	BCLI	2.09	N/A	N/A	0
2025-01-10	BCLI	2.01	N/A	N/A	0
2025-01-13	BCLI	1.98	N/A	N/A	0
2025-01-14	BCLI	2.07	N/A	N/A	0
2025-01-15	BCLI	2.09	N/A	N/A	0
2025-01-16	BCLI	1.99	N/A	N/A	0
2025-01-17	BCLI	1.88	N/A	N/A	0
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2024-12-19	BCLI	2.03	81.3	-	-2.31
2024-12-20	BCLI	2.27	81.3	-	-2.10
2024-12-23	BCLI	2.07	82.0	-	-2.10
2024-12-24	BCLI	2.23	82.0	-	-2.10
2024-12-26	BCLI	2.48	82.0	-	-2.10
2024-12-27	BCLI	2.45	82.0	-	-2.10
2024-12-30	BCLI	2.39	82.0	-	-2.10
2024-12-31	BCLI	2.27	82.0	-	-2.10
2025-01-02	BCLI	2.14	82.0	-	-2.10
2025-01-03	BCLI	2.23	82.0	-	-2.10
2025-01-06	BCLI	2.29	82.0	-	-2.10
2025-01-07	BCLI	2.23	82.0	-	-2.10
2025-01-08	BCLI	2.09	82.0	-	-2.10
2025-01-09	BCLI	2.09	82.0	-	-2.10
2025-01-10	BCLI	2.02	82.0	-	-2.10
2025-01-13	BCLI	2.02	82.0	-	-2.10
2025-01-14	BCLI	2.06	82.0	-	-2.10
2025-01-15	BCLI	2.05	82.0	-	-2.10
2025-01-16	BCLI	2.01	82.0	-	-2.10
2025-01-17	BCLI	1.89	82.0	-	-2.10
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2024-12-19	BCLI	-4.89	-2.50	3.00
2024-12-20	BCLI	-4.89	-2.50	3.00
2024-12-23	BCLI	-4.48	-2.60	3.00
2024-12-24	BCLI	-4.48	-2.60	3.00
2024-12-26	BCLI	-4.55	-2.60	3.08
2024-12-27	BCLI	-4.89	-2.60	3.08
2024-12-30	BCLI	-4.95	-2.60	3.08
2024-12-31	BCLI	-4.95	-2.60	3.08
2025-01-02	BCLI	-5.09	-2.60	3.08
2025-01-03	BCLI	-4.89	-2.60	3.08
2025-01-06	BCLI	-4.70	-2.60	3.08
2025-01-07	BCLI	-4.70	-2.60	3.08
2025-01-08	BCLI	-4.89	-2.60	3.08
2025-01-09	BCLI	-3.15	-2.60	3.39
2025-01-10	BCLI	-3.15	-2.60	3.39
2025-01-13	BCLI	-2.98	-2.60	2.11
2025-01-14	BCLI	-2.98	-2.60	2.11
2025-01-15	BCLI	-2.98	-2.60	2.11
2025-01-16	BCLI	-2.99	-2.60	2.11
2025-01-17	BCLI	-2.99	-2.60	2.11
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

-1.8

Avg. EPS Est. Current Quarter

-0.27

Avg. EPS Est. Next Quarter

Insider Transactions

-2.99

Institutional Transactions

-2.6

Beta

0.27

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

99.3

Max Drawdown 5-Year %

-99.6

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

-3.49

Average EPS Est. Cur. Y

-2.1

EPS Next Y. (Est.)

-1.59

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

0.7

Return on Equity vs Sector %

215.8

Return on Equity vs Industry %

228.4

EPS 1 7Days Diff

0.2

EPS 1 30Days Diff

0.21

EBIT Estimation

Brainstorm Cell Therapeutics In

Sector: Healthcare

Industry: Biotechnology

Employees: 29

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.

stock quote shares BCLI – Brainstorm Cell Therapeutics, Inc. Stock Price stock today

news today BCLI – Brainstorm Cell Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch BCLI – Brainstorm Cell Therapeutics, Inc. yahoo finance google finance

stock history BCLI – Brainstorm Cell Therapeutics, Inc. invest stock market

stock prices BCLI premarket after hours

ticker BCLI fair value insiders trading

Investment involves risk. As a general rule, you should only trade in financial products that you are familiar with and understand the risk associated with them. The risk warning described in each financial product below is not exhaustive, you should carefully consider your investment experience, financial situation, investment objective, risk tolerance level and consult your independent financial adviser as to the suitability of your situation prior making any investment.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: BCLI

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Get Started

About

Last Quarter Act. EPS

Average EPS Est. Cur. Y